ADDPI 2022_243 INADA vs Pallavi Jagadale

In August 2022 the India National Anti-Doping Agency (INADA) has reported an anti-doping rule violation against the Athlete Pallavi Jagadale (19) after her sample tested positive for the prohibited substance Darbepoetin (dEPO).

Following notification a provisional suspension was ordered. The Athlete filed a statement in her defence and she was heard for the Anti-Doping Disciplinary Panel of India (ADDPI).

The Athlete claimed that she is a young athlete and had never received anti-doping education. She was unable to find the source of the prohibited substance. She only had received an injection from a supplement supplier containing a doping free muscle relaxer.

The Panel finds that the presence of a prohibited substance has been established in the Athlete's sample and accordingly that she committed an anti-doping rule violation. In view of her significant negligence the Panel deems that the Athlete had acted intentionally.

The Panel did not accept that the Athlete had received an injection with an unknown substance without consultation of a doctor, coach or trainer. Neither accepts the Panel that the Athlete has a disadvantaged background, nor that she was inexperienced with anti-doping considering the multiple tests she was subjected.

Therefore the ADDPI Panel decides on 27 February 2023 to impose a 4 year period of ineligibility on the Athlete, starting on the date of the provisional suspension, i.e. on 3 August 2022.

Original document

Parameters

Legal Source
National Decisions
Date
27 March 2023
Arbitrator
Ghadlinge, Manik S.
Kumar, Akhil
Mahajan, Chaitanya
Original Source
India National Anti-Doping Agency (INADA)
Country
India
Language
English
ADRV
Adverse Analytical Finding / presence
Legal Terms
Case law / jurisprudence
Intent
Sport/IFs
Athletics (WA) - World Athletics
Other organisations
Anti-Doping Disciplinary Panel of India (ADDPI)
India National Anti-Doping Agency (INADA)
Laboratories
New Delhi, India: National Dope Testing Laboratory
Doping classes
S2. Peptide Hormones, Growth Factors
Substances
Darbepoetin (dEPO)
Document type
Pdf file
Date generated
16 March 2023
Date of last modification
11 April 2023
Category
  • Legal Source
  • Education
  • Science
  • Statistics
  • History
Country & language
  • Country
  • Language
Other filters
  • ADRV
  • Legal Terms
  • Sport/IFs
  • Other organisations
  • Laboratories
  • Analytical aspects
  • Doping classes
  • Substances
  • Medical terms
  • Various
  • Version
  • Document category
  • Document type
Publication period
Origin